Efficacy and safety of finerenone in diabetic kidney disease: Latin American experience from FINDKDLATAM trial

doi:10.5527/wjn.v15.i1.115933

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 1

This Article

(33)

(48)

(0)

(1088)

(2)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Nephrol. Mar 25, 2026; 15(1): 115933
Published online Mar 25, 2026. doi: 10.5527/wjn.v15.i1.115933

Table 1 Socio-demographic characteristics and relevant background of study population, median (interquartile rage)

	n	%
Gender
Female	153	44.1
Male	194	55.9
Age	65 (55-71)
< 65 years	173	49.9
65-79 years	157	45.2
≥ 80 years	17	4.9
Relevant background
AHT	294	84.7
Cardiovascular disease¹	148	42.7
Obesity	113	32 6
AMI	73	21.0
Smoking	56	16.1
Treatment
SGLT2i	293	84.4
RASSI	212	61.1
GLP-1	73	21.0
Finerenone dosage
10	194	55.9
20	153	44.1

¹Cardiovascular disease: Nonfatal acute myocardial infarction, nonfatal stroke, heart failure, peripheral arterial disease.

AHT: Arterial hypertension; AMI: Acute myocardial infarction; SGLT2i: Sodium-glucose cotransporter inhibitor; RASSI: Renin-angiotensin-system inhibitors; GLP-1: Glucagon-like peptide-1.

Full Size Table

Citation: Arnedo RD, Polo VS, Garcia JB, Gutiérrez JF, Clason ER, Domínguez D, Rebutti GM, Mancia CM, López RT, Meza MR, López DT, Muñoz Zambrano JJ, Herrera EL, Dina-Batlle E, Terrones MC, de Moraes TP, Yánez TR, Osorio W, Cabeza AA, Rico-Fontalvo J. Efficacy and safety of finerenone in diabetic kidney disease: Latin American experience from FINDKDLATAM trial. World J Nephrol 2026; 15(1): 115933
URL: https://www.wjgnet.com/2220-6124/full/v15/i1/115933.htm
DOI: https://dx.doi.org/10.5527/wjn.v15.i1.115933

Arnedo RD, Polo VS, Garcia JB, Gutiérrez JF, Clason ER, Domínguez D, Rebutti GM, Mancia CM, López RT, Meza MR, López DT, Muñoz Zambrano JJ, Herrera EL, Dina-Batlle E, Terrones MC, de Moraes TP, Yánez TR, Osorio W, Cabeza AA, Rico-Fontalvo J. Efficacy and safety of finerenone in diabetic kidney disease: Latin American experience from FINDKDLATAM trial. World J Nephrol 2026; 15(1): 115933 [PMID: 41884241 DOI: 10.5527/wjn.v15.i1.115933]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.